^
Association details:
| Biomarker: | MGMT promoter methylation |
|---|---|
| Cancer: | Anaplastic Astrocytoma |
| Drug: | temozolomide (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Excerpt:
...we enrolled patients with confirmed anaplastic astrocytoma or glioblastoma...MGMT promoter methylation was associated with longer overall survival than was unmethylated status (11·9 months [95% CI 9·0 to not reached] vs 8·2 months [7·0-10·0]; HR 0·62, 95% CI 0·42-0·91, p=0·014). EFS was longer in patients with MGMT promoter methylation who received temozolomide...
DOI:
10.1016/S1470-2045(12)70164-X
Trial ID:
